Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients

Author(s):
Maksymowych, W.P.; Heijde, D. van der; Baraliakos, X.; Deodhar, A.; Sherlock, S.P.; Li, D.; Fleishaker, D.; Hendrikx, T.; Kanik, K.S.
Published
2018
Publication type
Article / Letter to editor
ankylosing spondylitisinflammationmagnetic resonance imagingminimally important changesacroiliac jointsspineSPondyloArthritis Research Consortium of Canadatofacitinib
Date issued
2018-08-31
Language
English
Is part of
Rheumatology (2018), Vol. 57, no. 8, p. 1390-1399
hdl
1887/77653
doi
10.1093/rheumatology/key104
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055606/pdf/key104.pdf